A5088187030- Monoclonal and Polyclonal Antibodies Research
- CAR-T cell therapy research
- vaccines and immunoinformatics approaches
- CRISPR and Genetic Engineering
- Biochemical and Structural Characterization
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Chemical Synthesis and Analysis
- Glycosylation and Glycoproteins Research
- T-cell and B-cell Immunology
- Immune cells in cancer
- Viral Infectious Diseases and Gene Expression in Insects
- Immune Cell Function and Interaction
- Advanced Biosensing Techniques and Applications
Radboud University Nijmegen
2019-2024
Radboud University Medical Center
2019-2024
Radboud Institute for Molecular Life Sciences
2019-2023
Oncode Institute
2020-2023
University Medical Center
2019
Despite the clinical success of immune checkpoint blockade (ICB), in certain cancer types, most patients with do not respond well. Furthermore, for whom ICB is initially successful, this often short-lived because development resistance to ICB. The mechanisms underlying primary or secondary are incompletely understood. Here, we identified preferential activation and enhanced suppressive capacity regulatory T cells (Treg cells) αPD-L1 therapy-resistant solid tumor-bearing mice. Treg cell...
Functionalized antibodies and antibody fragments have found applications in the fields of biomedical imaging, theranostics, antibody–drug conjugates (ADC). In addition, therapeutic theranostic approaches benefit from possibility to deliver more than one type cargo target cells, further challenging stochastic labeling strategies. Thus, bioconjugation methods reproducibly obtain defined homogeneous bearing multiple different molecules, without compromising affinity, are demand. Here, we...
Hybridoma technology is instrumental for the development of novel antibody therapeutics and diagnostics. Recent preclinical clinical studies highlight importance isotype therapeutic efficacy. However, since sequence encoding constant domains fixed, tuning function in hybridomas has been restricted. Here, we demonstrate a versatile CRISPR/HDR platform to rapidly engineer immunoglobulin obtain recombinant hybridomas, which secrete antibodies preferred format, species, isotype. Using this...
Abstract Background While immune checkpoint inhibitors such as anti-PD-L1 antibodies have revolutionized cancer treatment, only subgroups of patients show durable responses. Insight in the relation between clinical response, PD-L1 expression and intratumoral localization therapeutics could improve patient stratification. Therefore, we present modular synthesis multimodal antibody-based imaging tools for multiscale to study distribution therapeutics. Results To introduce modalities, a peptide...
Cancer vaccines are a promising strategy to increase tumor-specific immune responses in patients who do not adequately respond checkpoint inhibitors. that contain patient-specific tumor antigens most effective but also necessitate the production of vaccines. This study aims develop versatile cancer vaccine format which can be site-specifically conjugated by proximity-based Sortase A (SrtA)-mediated ligation (PBSL) approach antibodies specifically bind antigen-presenting cells stimulate...
Optimal targeting of nanoparticles (NP) to dendritic cells (DCs) receptors deliver cancer-specific antigens is key the efficient induction anti-tumour immune responses. Poly (lactic-co-glycolic acid) (PLGA) containing tètanus toxoid and gp100 melanoma-associated antigen, toll-like receptor adjuvants were targeted DC-SIGN in DCs by specific humanized antibodies or ICAM3-Fc fusion proteins, which acts as natural ligand. Despite higher binding uptake efficacy anti-DC-SIGN antibody-targeted NP...
Development of the hybridoma technology by Köhler and Milstein (1975) has revolutionized immunological field enabling routine use monoclonal antibodies (mAbs) in research development efforts, resulting their successful application clinic today. While recombinant good manufacturing practices production technologies are required to produce clinical grade mAbs, academic laboratories biotechnology companies still rely on original lines stably effortlessly high antibody yields at a modest price....
Regulatory T cells (Tregs) are major drivers behind immunosuppressive mechanisms and present a hurdle for cancer therapy. Tregs characterized by high expression of CD25, which is potentially valuable target Treg depletion to alleviate immune suppression. The preclinical anti-CD25 (αCD25) antibody, clone PC-61, has met with modest anti-tumor activity due its capacity clear from the circulation lymph nodes, but not those that reside in tumor. optimization Fc domain this antibody been shown...
Abstract Optimal targeting of nanoparticles (NP) to dendritic cells (DCs) receptors deliver cancer-specific antigens is key an efficient induction anti-tumor immune responses. Poly (lactic-co-glycolic acid) (PLGA) containing tètanus toxoid and gp100 melanoma-associated antigen, toll-like receptor adjuvants were targeted the DC-SIGN in DCs by specific humanized antibodies or ICAM3-Fc fusion proteins mimicking natural ligand. Despite higher binding uptake efficacy anti-DC-SIGN...
Abstract Hybridoma technology is instrumental for the development of novel antibody therapeutics and diagnostics. Recent preclinical clinical studies highlight importance isotype therapeutic efficacy. However, since sequence encoding constant domains fixed, tuning function in hybridomas has been restricted. Here, we demonstrate a versatile CRISPR/HDR platform to rapidly engineer immunoglobulin obtain recombinant which secrete antibodies preferred format, species isotype. Using this platform,...
I. Abstract Functionalized antibodies and antibody fragments have found applications in the fields of biomedical imaging, theragnostics, antibody-drug conjugates (ADC). Antibody functionalization is classically achieved by coupling payloads onto lysine or cysteine residues. However, such stochastic strategies typically lead to heterogenous products, bearing a varying number payloads. This affects bioconjugate efficacy stability, as well its vivo biodistribution, therapeutic index, while...